Approximately 90% of people with CF (pwCF) in the United States carry at least one mutant CFTR allele that is compatible with highly effective modulator therapy (HEMT), a triple combination of the small molecules VX-445, VX-661, and VX-770 (elexacaftor/tezacaftor/ivacaftor or E/T/I) (37). The gene discussed is CFTR; the disease is cystic fibrosis.